An educated approach: AI-enabled neoantigen vaccine R&D
Cell & Gene Therapy Insights 2020; 6(4), 591–595
Published: 14 May 2020
Roman Yelensky is Gritstone Oncology’s first employee and serves as chief technology officer, with responsibility for the EDGE™ tumor antigen identification platform. Previously, Dr Yelensky was vice president at Foundation Medicine, which he joined at its inception. At Foundation Medicine, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Dr Yelensky established Foundation Medicine’s FDA-regulated products program, leading to FDA approval of the first NGS-based companion diagnostic. He holds a PhD in bioinformatics and genomics from the Massachusetts Institute of Technology and has co-authored more than 75 manuscripts, including most recently on EDGE in Nature Biotechnology.